Clinical outcomes in metastatic renal cell carcinoma (mRCC) treated with combination of nivolumab and cabozantinib (nivo-cabo) in the salvage setting.

被引：1
|
作者：
Ravindranathan, Deepak
Liu, Yuan
Martini, Dylan J.
Nazha, Bassel
Brown, Jacqueline T.
Russler, Greta
Yantorni, Lauren Beth
Caulfield, Sarah
Master, Viraj A.
Carthon, Bradley Curtis
Kucuk, Omer
Bilen, Mehmet Asim
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[2] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA USA
[3] Emory Univ, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA USA
[4] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16570
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Amin, A.
    BJU INTERNATIONAL, 2014, 114 : 8 - 8
  • [32] Phase 2 trial for sequential treatment of high dose cabozantinib (CABO) or CABO plus nivolumab (NIVO) on/after progression on CABO monotherapy in advanced renal cell carcinoma (RCC): Seq-Cabo
    Qin, Qian
    Brugarolas, James
    Hammers, Hans J.
    Arafat, Waddah
    Courtney, Kevin Dale
    Wang, Jue
    Jiang, Changchuan
    Zhang, Song
    Cowey, Charles Lance
    Hutson, Thomas E.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Rini, B. I.
    McDermott, D.
    Lewis, L.
    Voss, M. H.
    Sharma, P.
    Pal, S. K.
    Razak, A.
    Kollmannsberger, C. K.
    Heng, D.
    Spratlin, J.
    McHenry, B.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
    McGregor, B. A.
    Paul, M.
    Xie, W.
    Xu, W.
    Bilen, M. A.
    Braun, D. A.
    Berg, S.
    Zhang, T.
    McKay, R. R.
    McDermott, D. F.
    Hammers, H.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1020 - S1020
  • [35] Real-world (RW) treatment (tx) patterns and clinical outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) in the US community setting.
    Brown-Bickerstaff, Cherrishe
    Conkling, Paul R.
    Banuelos, Rosa
    Perez-Torrealba, Jose Ricardo
    Hall, Tasha D.
    Samant, Navendu
    Zhang, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [36] Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
    Brown, Landon C.
    Desai, Kunal
    Wei, Wei
    Kinsey, Emily N.
    Kao, Chester
    George, Daniel J.
    Rini, Brian, I
    Ornstein, Moshe C.
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
  • [37] Clinical outcomes in patients with chronic hepatitis C and metastatic renal cell carcinoma (mRCC) after treatment with nivolumab.
    Tsimafeyeu, Ilya
    Gafanov, Rustem
    Semenova, Anna
    Oganesyan, Ani
    Bondarenko, Anastasia
    Safina, Sufia
    Zakurdaeva, Kristina
    Protsenko, Svetlana
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 32 - 32
  • [38] Association of microbiome to nivolumab response in metastatic renal cell carcinoma (mRCC)
    Maia, Manuel
    Poroyko, Valeriy
    Won, Hae
    Bergerot, Paulo
    Almeida, Lorena
    Dizman, Nazli
    Hsu, JoAnn
    Jones, Jeremy
    Salgia, Ravi
    Pal, Sumanta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [39] Cabozantinib (Cabo) concentration (Cmin) association with toxicity (tox) and treatment failure in metastatic renal cell carcinoma (mRCC) patients: The MONICA study
    Cerbone, L.
    Combarel, D.
    Geraud, A.
    Foulon, S.
    Silva, Carolina Alves Costa
    Colomba-Blameble, E.
    Derosa, L.
    Guida, A.
    Flippot, R.
    Carril-Ajuria, L.
    Mir, O.
    Escudier, B.
    Paci, A.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S569 - S570
  • [40] Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.
    Hirsch, Laure
    Chanza, Nieves Martinez
    Farah, Subrina
    Flippot, Ronan
    Rathi, Nityam
    Collier, Katharine
    de Velasco, Guillermo
    Seront, Emmanuel
    Beuselinck, Benoit
    Xu Wenxin
    Bowman, Isaac Alexander
    Lam, Elaine Tat
    Dzimitrowicz, Hannah Elizabeth
    Zakharia, Yousef
    McKay, Rana R.
    Bilen, Mehmet Asim
    Albiges, Laurence
    Xie Wanling
    Harshman, Lauren C.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345